mRNA vaccine did wonders to contain deadly Coronavirus or COVID-19 cases all over the globe. mRNA or messenger RNA is a molecule that contains the instructions or recipe that directs the cells to make a protein using its natural machinery. To enter cells smoothly, mRNA travels within a protective bubble called a Lipid Nanoparticle. Once inside, our cells read the mRNA as a set of instructions, building proteins that match up with parts of the pathogen called antigens. The immune system sees these foreign antigens as invaders – dispatching defenders called antibodies and T-cells – and training the immune system for potential future attacks. So, if and when the real virus comes along, the body might recognize it – sounding the alarm to help defend against infection and illness. India has not lagged behind and has developed indigenously first mRNA vaccine against the COVID-19 and has got the Emergency Use Authorization (EUA), to be sold under the brand name GEMCOVAC™-19 and will be rolled out soon. The vaccine will be available for adults above 18 years of age. It is a two-dose vaccine to be administered intramuscularly at 28 days apart. The Pune-based subsidiary of Emcure Pharmaceuticals Ltd, Gennova Biopharmaceuticals Ltd. announced that its mRNA vaccine - GEMCOVAC™-19 - against COVID-19 received the Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI). GEMCOVAC-19™ is the very first mRNA vaccine developed in India and the only third mRNA vaccine to be approved for COVID-19 in the world. These vaccines are highly efficacious because of their inherent capacity of being translated into the protein structure inside the cell cytoplasm. It's India's first mRNA vaccine, only the third vaccine based on this platform to get this authorization globally, and the fact this vaccine is stable at two to eight degrees Celsius. The company should ensure that the distribution is entirely guided by the government and it has also to confirm that major side effects were at the bay during trials. The mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. Notably, this technology provides flexibility to quickly tweak the vaccine for any existing or emerging variants of the virus and this technology platform will empower India to be pandemic ready. Genova's GEMCOVAC™-19 has reached the primary endpoint of the Phase III clinical trial. As per the Central Drugs Standard Control Organisation, the clinical data evaluated showed that the vaccine was found to be safe, well-tolerated, and immunogenic.